Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nuvalent, Inc. (NUVL : NSDQ)
 
 • Company Description   
Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 40

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.06 Daily Weekly Monthly
20 Day Moving Average: 121,466 shares
Shares Outstanding: 48.31 (millions)
Market Capitalization: $389.41 (millions)
Beta:
52 Week High: $40.82
52 Week Low: $7.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -27.06% -17.85%
12 Week -47.35% -42.13%
Year To Date -57.67% -51.55%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
One Broadway 14thFloor
-
Cambridge,MA 02142
USA
ph: 857-357-7000
fax: -
None http://www.nuvalent.com
 
 • General Corporate Information   
Officers
James R. Porter - President and Chief Executive Officer
Alexandra Balcom - Chief Financial Officer
Emily Drabant Conley - Director
Andrew A. F. Hack - Director
Robert Jackson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 670703107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/14/22
Share - Related Items
Shares Outstanding: 48.31
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $389.41 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.87 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/14/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.45
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -28.29
12/31/21 - -34.42
09/30/21 - -
ROA
03/31/22 - -22.34
12/31/21 - -24.87
09/30/21 - -
Current Ratio
03/31/22 - 33.78
12/31/21 - 33.08
09/30/21 - 44.60
Quick Ratio
03/31/22 - 33.79
12/31/21 - 33.07
09/30/21 - 44.60
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 5.57
12/31/21 - 5.90
09/30/21 - 6.24
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©